Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lilly's Mounjaro Now Approved to Reduce Cardiovascular Risk in T2D

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Health: Biotech

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

Eli Lilly's Mounjaro (tirzepatide) has received FDA approval to reduce cardiovascular risk in adults with type 2 diabetes based on the SURPASS-CVOT trial showing noninferiority to dulaglutide in reducing major adverse cardiovascular events.

This Wire brief sits within Fusion42's coverage of Health: Biotech, and 8 sources have reported it.

◆ ◆ The Wire takeaway

Your type 2 diabetes product now competes with Mounjaro's expanded label for cardiovascular risk, pressing urgency on differentiating beyond glycemic control. Cardiometabolic-focused Biotech founders must note this FDA nod opens new market demands for comprehensive risk reduction.

◆ Coverage

8 sources · 28 Aug 2026

◆ Topics

Health: Biotechcardiovascularfda-approvaltype-2-diabetestirzepatideclinical-trial